Compare
Longeveron Inc. vs China SXT Pharmaceuticals, Inc. vs IGC Pharma, Inc. vs Bespoke Extracts, Inc.
| Latest fiscal year | Longeveron Inc. LGVN | China SXT Pharmaceuticals, Inc. SXTC | IGC Pharma, Inc. IGC | Bespoke Extracts, Inc. BSPKLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-03-31 | 2024-12-31 |
| Revenue | $1.20M | $1.14M | $1.27M | $1.12M |
| Revenue growth (YoY) | -49.9% | -34.6% | -5.5% | +42.3% |
| Gross margin | 67.0% | 21.9% | 48.7% | 40.5% |
| Operating margin | n/m | -625.9% | -585.8% | -89.0% |
| Net margin | n/m | -545.2% | -560.3% | -92.8% |
| Net income | -$22.70M | -$6.21M | -$7.12M | -$1.04M |
| EPS (Diluted) | -$1.29 | -$9.13 | -$0.09 | -$0.10 |
| Operating cash flow | -$18.64M | -$4.02M | -$4.79M | -$289.8K |
| Free cash flow | -$18.89M | n/a | -$4.91M | -$889.8K |
| Cash & equivalents | $4.66M | $28.18M | $405.0K | n/a |
| Total assets | $10.26M | $34.75M | $8.75M | $359.1K |
| Total liabilities | $4.59M | $5.05M | $2.42M | $2.45M |
| Shareholders' equity | $5.67M | $29.71M | $6.33M | -$2.09M |
| Return on year-end equity | -400.1% | -20.9% | -112.5% | n/a |
| Shares outstanding | n/a | n/a | 80.88M | 11.15M |
Revenue, most recent five fiscal years
| Fiscal year | Longeveron Inc. | China SXT Pharmaceuticals, Inc. | IGC Pharma, Inc. | Bespoke Extracts, Inc. |
|---|---|---|---|---|
| Latest | $1.20M Ended 2025-12-31 | $1.14M Ended 2026-03-31 | $1.27M Ended 2025-03-31 | $1.12M Ended 2024-12-31 |
| 1 year earlier | $2.39M Ended 2024-12-31 | $1.74M Ended 2025-03-31 | $1.34M Ended 2024-03-31 | $785.5K Ended 2023-12-31 |
| 2 years earlier | $709.0K Ended 2023-12-31 | $1.93M Ended 2024-03-31 | $911.0K Ended 2023-03-31 | $3.4K Ended 2022-12-31 |
| 3 years earlier | $1.22M Ended 2022-12-31 | $1.97M Ended 2023-03-31 | $397.0K Ended 2022-03-31 | n/a |
| 4 years earlier | $1.31M Ended 2021-12-31 | $2.60M Ended 2022-03-31 | $898.0K Ended 2021-03-31 | n/a |